Recent

% | $
Quotes you view appear here for quick access.

Nano Labs Corp. Message Board

gadzillionman 69 posts  |  Last Activity: 1 hour 47 minutes ago Member since: Feb 19, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    CFO resignation

    by expat_2002_2014 Apr 28, 2016 11:35 AM
    gadzillionman gadzillionman Apr 28, 2016 2:15 PM Flag

    Since the matter is personal , lets just let it be, I doubt his departure will have any impact on SGYP being sold to AGN. Long SGYP

    Sentiment: Buy

  • Allergan

    Pharmaceutical Sales Representative

    Apply Now
    Pasadena, CA
    Date posted: April 26 2016


    In early 2015, Actavis completed the acquisition of Allergan. This combination united two growing, successful and profitable companies into a unique, global pharmaceutical company and a leader in a new industry model - Growth Pharma. In June 2015, the combined company changed its corporate name to Allergan plc and its stock ticker to NYSE:AGN.

    Today, our nearly 30,000 talented global employees are creating an unrivaled foundation for long-term growth. We combine highly regarded brands and a best-in-class generics business with an enviable pipeline and lean, reliable operations to drive value for customers.

    Join one of the world’s fastest growing specialty pharmaceutical companies!

    At Allergan you will have the opportunity to thrive in a fast-paced, strategic environment where bold, innovative thinking isn’t just welcomed, it’s encouraged. Across all functions, we relish the opportunity to help our people fulfill their potential. Our rapid growth strategy means plenty of stretch assignments and opportunities to step into the spotlight.

    Position Description:

    As a pharmaceutical Sales Representative, you will have the opportunity to regularly call on health care professionals (primary care physicians, clinics, hospitals and pharmacies) within a specific geographic area. Day-to-day responsibilities consist of supporting the promotional efforts behind Allergan products, which includes organizing, tracking and distributing FDA regulated sample products to health care professionals. You will maintain a current and competent level of knowledge on the product line to be a reliable source of information to the health care professionals in the territory.

    Experience :
    • Candidates should possess a minimum of 1 year of experience in outside business to business sales with a proven track record of success.
    • Ability to work bot

    Sentiment: Strong Buy

  • gadzillionman by gadzillionman Apr 29, 2016 10:01 AM Flag

    I've been seeing several articles about both companies in advanced talks with an announcement being imminent & if you dig a little deeper they have placed a value of 3.6 b this would imply that they are giving their best bid to close deal quickly & to shut out Shire. If that is the offer & a very good one then that makes the PPS around $31 a share based on 113 m shares. Would someone offer some technical info regarding debt ,warrants etc & how much per share investors would get, we have to keep in mind that AGN may throw in some stock with this deal although they wouldn't need to , thanks I'm a fundamental investor

    Sentiment: Strong Buy

  • Reply to

    value per share in a AGN/SGYP BO ?

    by gadzillionman Apr 29, 2016 10:01 AM
    gadzillionman gadzillionman Apr 29, 2016 12:34 PM Flag

    SGYP website & Yahoo says 113m but I have seen the 150m only on 1 website, so who knows, that IS the amount that both sides are agreeing on & the source says the deal could be announced soon.... whoever thinks SGYP will be sold for a billion is a complete moron as the cost to get this far is around 1.5b + Paulson is not in this for a mere $2 upside & neither is the other 60 hedge funds !!!!! 3.6b is the offer because no one will bid more, this is AGN strategy to acquire SGYP quickly as they do not want a bidding war. Deal announcement may be next Mon ?

  • gadzillionman by gadzillionman Apr 29, 2016 3:20 PM Flag

    watch out longs, I have more cash than they do, lol unless they get bought soon, investors will suffer , got out @ 14

    Sentiment: Strong Sell

  • Reply to

    dilution coming !!!!

    by gadzillionman Apr 29, 2016 3:20 PM
    gadzillionman gadzillionman Apr 29, 2016 3:34 PM Flag

    I'm not greedy...... still got a $4.78 upside on $ 3,500 shares

  • Looking ahead
    Given its late-stage trial success in boosting overall survival -- the gold standard of any cancer study -- it would seem that Celator Pharmaceuticals has indeed built something that could significantly improve the standard of care and, in turn, make this company one worth watching.

    However, investors might want to keep some of their enthusiasm in check, at least until we get more insight into the efficacy of next-generation immunotherapies that are being developed for the indication.

    Juno Therapeutics (NASDAQ:JUNO) is conducting a phase 1/2 study of its JTCR016 in AML, and results from that trial could be available in the first half of next year. Also, Kite Pharma (NASDAQ:KITE) has teamed up with Amgen (NASDAQ:AMGN) to discover next-generation immuno-therapies that could be used in AML, too.

    Juno Therapeutics and Kite Pharma's efforts are admittedly in the earliest of stages of research. Thus, Celator Pharmaceuticals could have some running room that makes it appropriate for risk-tolerant investors. Nevertheless, investors will want to keep a close eye on Juno Therapeutics and Kite Pharma's progress, because their immuno-therapies could challenge Vyxeos in this indication someday.

    Sentiment: Hold

  • gadzillionman by gadzillionman May 3, 2016 10:10 AM Flag

    Lets see if Gadz is right ?

    Sentiment: Strong Buy

  • Reply to

    Allergan bidding 3.6B

    by gadzillionman May 3, 2016 10:10 AM
    gadzillionman gadzillionman May 3, 2016 6:37 PM Flag

    It's called research , the info I found cannot be copied & pasted to this message board , but with 180m shares in all, that would imply about a $20 buyout , so that would be a reasonable amount & Allergan will have about 33B soon, so money wont be an issue, they want SGYP bad !!! Gadz is long SGYP of course & no need to pump anything , I plan on making lots of profit very soon.

    Sentiment: Strong Buy

  • Another possible acquisition target would be New York-based Synergy Pharmaceuticals. Today Synergy announced that the U.S. Food and Drug Administration (FDA) had given a PDUFA target of Jan. 29, 2017 for plecanatide, the company’s first uroguanylin analog for the treatment of chronic idiopathic constipation (CIC).

    Jensen notes that Synergy’s drug appears to be better than the current market leader, Ironwood Pharmaceuticals (IRWD)’ Linzess, which makes about $450 million in annual sales, but projects to be able to hit $1 billion by 2020. Synergy has an enterprise value of about $400 million.

    And others have offered up Cambridge, Mass.-based Biogen (BIIB) as a potential target, as well as North Chicago, Ill.-based AbbVie (ABBV), Celgene (CELG), Bristol-Myers Squibb (BMY) or AstraZeneca (AZN).

    If Allergan opted for smaller buys in the dermatology market, it might consider Revance Therapeutics (RVNC), Anacor Pharma (ANAC) or Dermira.

    Sentiment: Buy

  • gadzillionman by gadzillionman May 6, 2016 9:30 AM Flag

    Synergy Pharma Seen 'Weighing' Options, Sell-Side Forecasts Upside Regardless Of M&A Rumors



    Benzinga News Desk , Benzinga Staff Writer

    Follow 
    May 05, 2016 12:29pm Comments


    Trade with confidence. Are you a professional trader? Be the first to get the alert with Benzinga Pro's real-time newsfeed and audio squawk and never miss an opportunity again.
    Don't miss the chance to try it FREE today.

    Synergy Pharma Seen 'Weighing' Options, Sell-Side Forecasts Upside Regardless Of M&A Rumors

    Related SGYP

    Jim Cramer Gives His Opinion On Synergy Pharmaceuticals And ABIOMED

    10 Stocks Moving In Monday's Pre-Market Session



    Like many small-cap biotech stocks, Synergy Pharmaceuticals Inc
    SGYP
    is no stranger to the rumor mill. StreetInsider reported the company was exploring a sale on April 8, sending shares 8 percent higher.

    Bloomberg reported a similar rumor in March 2015, also yielding no follow-through.

    Little has happened on the M&A front since that report. News that Synergy's new drug application (NDA) for Plecanatide had been accepted by the FDA on April 19 pushed the stock up another 11 percent, leading analysts at Rodman & Renshaw and Roth Capital to reiterate bullish theses the next day.

    The NDA is now under review with a target PDUFA action date of January 29, 2017.

    Synergy Management Seen 'Weighing' Options

    So, if Synergy buyout chatter emerges again, should investors take it seriously? It depends on the timeline

    Roth's Michael Higgins told Benzinga this week that as far as he could tell, the company has not put itself on the block at the moment. However, he didn't rule it out over the long-term.

    Management, he said, is "weighing their options, doing what most companies do in their position: consider the market oppo

    Sentiment: Buy

  • Thank You & Happy Hunting
    Bret Jensen

    Founder, Biotech Forum

    Disclosure: I am/we are long ACAD, AGN, AMGN, ANIP, BIIB, RLYP, SGYP.

    Sentiment: Buy

  • 5 buyers & $25+ upside !!!! will take decent position on Mon. FYI: Take a look @ SGYP , a $3 stock with a BO price of $15+ with Allergan as the buyer, although it may be a few months away.... Long SGYP

    Sentiment: Buy

  • gadzillionman gadzillionman May 9, 2016 8:33 AM Flag

    Please don't post on YMB till that concussion from getting hit in the head with a golf ball goes away !! Allergan will be the buyer..... End of story

    Sentiment: Buy

  • gadzillionman gadzillionman May 10, 2016 7:53 PM Flag

    Nobody cares about taking a dollar less for their shares , go peddle your #$%$ somewhere else !!! BO will happen via Allergan for @ least $ 15 but I see $ 17 as being their offer, do you really think investors just shelled out 89m for a $1 upside lol

    Sentiment: Buy

  • SGYP 5/10/16 source: Nasdaq
    Settlement Date

    Short Interest

    Avg Daily Share Volume

    Days To Cover

    4/15/2016 17,333,427 3,635,354 4.768016
    3/31/2016 17,306,239 4,189,829 4.130536
    3/15/2016 27,282,159 2,016,319 13.530676
    2/29/2016 27,882,223 1,518,792 18.358158
    2/12/2016 28,077,534 1,956,089 14.353914
    1/29/2016 27,470,221 2,345,113 11.713815
    1/15/2016 27,720,760 3,679,906 7.533008
    12/31/2015 27,640,462 1,648,924 16.762726
    12/15/2015 28,666,708 1,349,576 21.241270
    11/30/2015 28,552,330 1,385,711 20.604823

    Sentiment: Buy

  • gadzillionman gadzillionman May 11, 2016 7:39 AM Flag

    The AGN deal is already in the works , do some more research !! AGN will be receiving 33b in cash from Teva in June ,so even if product launches cost a 1b, they will certainly be able to pay the cost or more. AGN may sell their 50% stake after deal or just dominate the GI market, AGN wants SGYP & they can & will outbid all others. Smart money is on the long side , the news broke about AGN in talks with SGYP around the same time that short interest fell by 10m shares, institutional investors have been buying more shares like Paulson & JP Morgan plus many more so no logical bear case to made , but longs are smarter than you ,please keep that in mind before you waste your time posting #$%$!!

    Sentiment: Buy

  • gadzillionman by gadzillionman May 11, 2016 9:03 AM Flag

    ...in $3.6B Deal:...Allergan(AGN) Takeover of Synergy ...(NYSE:AGN is in advanced talks to acquire Synergy Pharmaceuticals (Nasdaq...

    Sentiment: Buy

  • gadzillionman by gadzillionman May 12, 2016 8:37 AM Flag

    PACB & Roche cannot agree on a price to get deal done , the average analyst has placed a value of $20 per share, so not sure how far apart they are ? sold half my position @ 10.24 so I'm happy either way, there could be other buyers interested but haven't read any articles on subject. PACB @ least is good to trade for daily & weekly profits!!

    Sentiment: Buy

  • Reply to

    Why BO has stalled

    by gadzillionman May 12, 2016 8:37 AM
    gadzillionman gadzillionman May 12, 2016 9:10 AM Flag

    I doubt that could happen, because you would have an instant monopoly , I don't see much risk in the stock so happy just to hold , there must be @ least a $ 3-5 divergence with both sides not willing to talk anymore, it comes down to can PACB survive alone against a powerhouse like ILMN ? I'd say NO

CTLE
0.00010.0000(0.00%)12:59 PMEDT